206. 脆弱Ｘ症候群 Fragile X syndrome Clinical trials / Disease details

臨床試験数 : 108 / 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77

diseases per page:

Showing 1 to 10 of 108 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05301361 (ClinicalTrials.gov)	February 1, 2023	8/3/2022	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities	Sensitivity of the NIH Toolbox Cognition Battery to Stimulant Treatment in Intellectual Disabilities ...	Intellectual Disability;Fragile X Syndrome;Down Syndrome;Attention Deficit Hyperactivity Disorder	Drug: Methylphenidate Oral Solution	University of California, Davis	NULL	Recruiting	6 Years	17 Years	All	68	Phase 1	United States
2	NCT05358886 (ClinicalTrials.gov)	November 1, 2022	27/4/2022	A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome	A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Age ...	Fragile X Syndrome	Drug: BPN14770/ zatolmilast;Drug: Placebo	Tetra Discovery Partners	NULL	Recruiting	18 Years	45 Years	Male	150	Phase 3	United States
3	NCT05367960 (ClinicalTrials.gov)	November 1, 2022	29/4/2022	An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome	An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome	Fragile X Syndrome	Drug: Zatolmilast / BPN14770	Tetra Discovery Partners	NULL	Enrolling by invitation	12 Years	45 Years	Male	300	Phase 3	United States
4	NCT05418049 (ClinicalTrials.gov)	September 8, 2022	31/5/2022	Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge	Evaluating the Neurophysiologic and Clinical Effects of Single-Dose Baclofen, Roflumilast, Memantine ...	Fragile X Syndrome	Drug: Baclofen;Drug: Memantine;Drug: Roflumilast;Drug: Placebo	Children's Hospital Medical Center, Cincinnati	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Recruiting	18 Years	45 Years	All	45	Phase 2	United States
5	NCT04823052 (ClinicalTrials.gov)	May 25, 2022	24/3/2021	Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X SyndromePatients Age ...	A Phase 2, Placebo-controlled, Adaptive Design Study to Explore the Safety and Efficacy of Sulindac ...	Fragile X Syndrome	Drug: Sulindac (HLX-0201), dose strength 1;Drug: Sulindac (HLX-0201), dose strength 2;Drug: Placebo;Dr ...	Healx Limited	NULL	Withdrawn	13 Years	40 Years	Male	0	Phase 2	United States;Australia
6	NCT05163808 (ClinicalTrials.gov)	March 29, 2022	15/12/2021	A Randomized Study of BPN14770 in Male Adolescents (Aged 12 to < 18 Years) With Fragile X Syndrome	A Randomized, Double-blind, Placebo-controlled, Two-Part Study of High and Low Dose BPN14770 in Male ...	Fragile X Syndrome	Drug: zatolmilast;Drug: Placebo	Tetra Discovery Partners	NULL	Recruiting	12 Years	18 Years	Male	150	Phase 2/Phase 3	United States
7	NCT05120505 (ClinicalTrials.gov)	December 29, 2021	3/11/2021	Metformin in Children With Fragile X Syndrome	Efficacy and Safety of Metformin in the Treatment of Fragile X Syndrome	Fragile X Syndrome;Metformin	Drug: Metformin;Drug: Placebo	Children's Hospital of Fudan University	NULL	Recruiting	2 Years	16 Years	All	20	Phase 4	China
8	NCT05030129 (ClinicalTrials.gov)	October 7, 2021	5/8/2021	Single Blind Study of Ergoloid Mesylates, 5-HTP and the Combination in Adult Males With Fragile X Sy ...	An Exploratory Single Blind Study of Ergoloid Mesylates, 5-Hydroxytryptophan, and the Combination in ...	Fragile X Syndrome	Dietary Supplement: 5-Hydroxytryptophan / Vitamin B6;Drug: Ergoloid Mesylate;Other: Placebo	Elizabeth Berry-Kravis	NULL	Recruiting	18 Years	45 Years	Male	15	Phase 2	United States
9	NCT04977986 (ClinicalTrials.gov)	September 13, 2021	20/7/2021	Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome	A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 ...	Fragile X Syndrome	Drug: ZYN002 - transdermal gel;Drug: Placebo	Zynerba Pharmaceuticals, Inc.	NULL	Recruiting	3 Years	23 Years	All	204	Phase 3	United States;Australia;Ireland;United Kingdom
10	NCT04314856 (ClinicalTrials.gov)	January 12, 2021	11/3/2020	Novel Clinical Target in Fragile X Syndrome	Sigma-1 Receptors: A Novel Clinical Target in Fragile X Syndrome	Fragile X Syndrome (FXS)	Drug: 18F-FTC-146	Guido A. Davidzon, MD, SM	NULL	Withdrawn	18 Years	65 Years	All	0	Phase 1	United States

First Previous1 2 3 4 5…11Next Last